SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 5 of 26
Word Count: 1499
Character Count: 9646

Document Content:

reports we file with the SEC, among other things: ● our ability to compete in our industry, including against competitors that have significantly greater financial, technical and marketing resources than we do; ● our ability to respond to customer preferences and successfully develop new and innovative products in a timely manner and effectively manage the introduction of new or enhanced products; ● risks related to a loss of, or material cancellation, reduction, or delay in purchases by, one or more of our largest customers; ● our outside suppliers and manufacturers failing to supply products in sufficient quantities and in a timely fashion; ● our ability to execute on our strategic initiatives (including acquisitions); ● our ability to maintain the reputation of our brands; ● the risks related to consumers’ perception of the safety and quality of our products as well as similar products distributed by other companies in our industry;

●	the risks related to third parties asserting intellectual property
infringement claims against us;

●	the risks related to our planned expansion into additional international
markets;

●	the risks related to adverse economic conditions;

●	the risks related to catastrophic events;

●	our ability to retain key personnel, manage our business effectively,
and continue to grow;

●	the impact of numerous laws and regulations that apply to the
manufacture, sale, and manufacturing of nutritional supplements, and compliance with these laws and regulations, as they currently exist
or as modified in the future, on us and our suppliers;

●	the risks related to product recalls; and

●	the risks related to product liability claims and litigation
to prosecute such claims;

Any one or more of these uncertainties,
risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately
prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these
forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information,
future events or otherwise.

You should rely only on the
information in this prospectus and any related prospectus supplement. We have not authorized any other person to provide you with different
information. If anyone provides you with different or inconsistent information, you should not rely upon it.

USE OF PROCEEDS

Unless we inform you otherwise
in the prospectus supplement relating to a particular offering of securities, we will use the net proceeds from the sale of the securities
offered by this prospectus and the exercise price from the exercise of any convertible securities, if any, for research and development
expenses, working capital and other general corporate purposes, which may include funding acquisitions or investments in businesses, products
or technologies that are complementary to our own and reducing indebtedness.

When particular securities
are offered, the prospectus supplement relating to that offering will set forth our intended use of the net proceeds received from the
sale of those securities we sell. Pending the application of the net proceeds for these purposes, we expect to invest the proceeds in
short-term, interest-bearing instruments or other investment-grade securities.

THE SECURITIES WE MAY OFFER

General

The descriptions of the securities
contained in this prospectus, together with the applicable prospectus supplements, summarize all of the material terms and provisions
of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating to any securities
the particular terms of the securities offered by that prospectus supplement. If we indicate in the applicable prospectus supplement,
the terms of the securities may differ from the terms we have summarized below. We may also include in the prospectus supplement information
about material United States federal income tax considerations relating to the securities, and the securities exchange, if any, on which
the securities will be listed.

We may sell from
time to time, in one or more offerings:

●	common stock;

●	preferred stock;

●	warrants to purchase shares of our common stock or preferred stock;

●	debt securities;

●	subscription rights to purchase shares of common stock, preferred stock or debt securities; and

●	units consisting of any combination of the securities listed above.

In this prospectus, we refer
to the common stock, preferred stock, warrants, debt securities, subscription rights and units collectively as “securities.”
The total dollar amount of all securities that we may sell pursuant to this prospectus will not exceed $100 million.

If we issue debt securities
at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities
issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of
the debt securities.

This prospectus may not be
used to consummate a sale of securities unless it is accompanied by a prospectus supplement.

DESCRIPTION OF CAPITAL
STOCK

The following descriptions
are summaries of the material terms of our certificate of incorporation and amended and restated bylaws, to which you should refer. Reference
is made to the more detailed provisions of, and the descriptions are qualified in their entirety by reference to, the certificate of incorporation
and amended and restated bylaws, which are filed with the SEC as exhibits to the registration statement of which this prospectus is a
part, and applicable law.

General

Our authorized capital stock
consists of 300,000,000 shares of common stock, par value $0.00001 per share and 1,000,000 shares of undesignated preferred
stock, $0.00001 par value. On November 20, 2025 there were 11,431,926 shares of common stock issued and 11,251,853 shares of common stock
outstanding, held by approximately 68 stockholders of record. On November 20, 2025, no shares of preferred stock were issued or outstanding.

Common Stock

Dividend Rights

The holders of outstanding
shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our Board
of Directors may determine.

Voting Rights

Each holder of our common stock
is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Cumulative voting for
the election of directors is not provided for in our articles of incorporation, which means that the holders of a majority of our shares
of common stock voted can elect all of the directors then standing for election.

Preemptive or Similar Rights

Our common stock is not entitled
to preemptive rights and is not subject to conversion or redemption.

Liquidation Rights

Upon our liquidation, dissolution,
or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our
common stock outstanding at that time after payment of other claims of creditors.

Preferred Stock

Our articles of incorporation
provide that our Board of Directors is authorized to issue shares of preferred stock from time to time in one or more series. Our Board
of Directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional
or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series.

We will fix the designations,
powers, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereon,
in the certificate of designation relating to that series. The applicable prospectus supplement will contain the terms of and other information
relating to the preferred stock which will include, as applicable:

●	the title and stated value;

●	the number of shares we are offering;

●	the liquidation preference per share;

●	the purchase price; the dividend rate, period and payment date
and method of calculation for dividends;

●	whether dividends will be cumulative or non-cumulative and,
if cumulative, the date from which dividends will accumulate;

●	the procedures for any auction and remarketing, if any;

●	the provisions for a sinking fund, if any;

●	the provisions for redemption or repurchase, if applicable,
and any restrictions on our ability to exercise those redemption and repurchase rights;

●	any listing of the preferred stock on any securities exchange
or market;

●	whether the preferred stock will be convertible into our common
stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period;

●	voting rights, if any, of the preferred stock;

●	preemptive rights, if any;

●	restrictions on transfer, sale or other assignment, if any;

●	whether interests in the preferred stock will be represented
by depositary shares;

●	a discussion of any material United States federal income tax
considerations applicable to the preferred stock;

●	the relative ranking and preferences of the preferred stock
as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;

●	any limitations on the issuance of any class or series of preferred
stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve
or wind up our affairs; and